Clinical Trials (Phase I)
Filter News
Found 13,496 articles
-
Worldwide Clinical Trials Implements ClinSpark eSource Platform
10/17/2019
Innovative Technology Enables Nimble Phase I Services
-
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
10/17/2019
NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab) biosimilar candidate, NeuLara, in a Phase I clinical trial.
-
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
10/17/2019
Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 Inhibitor
-
Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease
10/17/2019
Nimacimab is a first-in-class negative-allosteric modulating antibody agonist to the cannabinoid 1 (CB1) receptor.
-
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes
10/16/2019
Findings further validate Cell Pouch and therapeutic cell performance in
-
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
10/16/2019
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).
-
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
10/16/2019
Hepagene Therapeutics, Inc announced that it has dosed the first healthy volunteer in a phase I clinical trial of HPG1860 in the United States.
-
Amphivena Initiates Solid Tumor Clinical Trial
10/16/2019
Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors
-
miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
10/16/2019
miRagen Therapeutics, Inc. announced new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin expression, which has been show to correlate with activation of myofibroblasts.
-
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
10/15/2019
Sustained wound healing and favorable safety profile observed at three years post-treatment
-
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialPreliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting
10/15/2019
Principia Biopharma Inc. announced positive preliminary data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in a highly treatment-resistant and refractory patient population with immune thrombocytopenia Further updated data from the trial will be presented at an oral scientific session at the 61st American Society of Hematology Annual Meeting in December
-
Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing
10/14/2019
AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms; AVID200 spares TGF-beta 2 for optimal safety
-
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial
10/14/2019
Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding
-
Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301
10/12/2019
Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eyes extended to four months or longer without receiving retreatment
-
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
10/12/2019
REGENXBIO Inc. announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a podium presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology 2019 Annual Meeting in San Francisco, CA.
-
Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the AAO Annual Meeting
10/12/2019
Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eyes extended to four months or longer without receiving retreatment
-
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative, Non-Viral Gene Therapy for Ocular Diseases at 11th Annual Ophthalmology Innovation Summit
10/11/2019
Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco
-
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
10/11/2019
Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks
-
Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.
10/11/2019
Kangpu Biopharmaceuticals announced that it has successfully completed a first-in-human phase I single ascending dose clinical study of KPG-818 conducted in the United States.
-
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
10/11/2019
Auris Medical Holding Ltd. announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.